Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...

Greenland will vote in a general election on Tuesday seen by some locals as a historic chance to free themselves from Danish ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Genmab A/S posted the largest decline among large stocks during the session, falling 8.3%, followed by Novo Nordisk A/S shares, which declined 8.1%. Shares of Torm PLC A declined 7.1%.

Flagship Pioneering-founded Valo Therapeutics says it has successfully secured a financing round of 19 million euros ($20.6 million), part of which was raised in Europe and part in Australia, to ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...